Health Care/Hospital
Dr. Eliza Fok, Chairman of the Hong Kong Breast Cancer Foundation Is Honoured with "Women of Power 2023" by Prestige Hong Kong
HONG KONG, Dec. 12, 2023 /PRNewswire/ -- Hong Kong Breast Cancer Foundation (HKBCF) is proud to announce that Dr. Eliza Fok, Chairman of HKBCF, has been honoured with "Women of Power 2023" by leadingHong Kong magazine Prestige Hong Kong. HKBCF extends its congratulations to Dr. Fok on this achie...
2023-12-12 17:58
1353
Illumina partners with HaploX to build a domestically produced flagship benchtop sequencing system
SHENZHEN, China, Dec. 12, 2023 /PRNewswire/ -- On December 9, Illumina, a global leader in DNA sequencing and array-based technologies, and HaploX, aChina -based high-tech company specializing in oncology liquid biopsy and genetic big data, jointly announced the official launch of the first NextSe...
2023-12-12 17:31
1941
WuXi Biologics Named to 2023 Dow Jones Sustainability World Index
* Identified as a global sustainability leader by S&P Global * Committed to generating long-term value for all stakeholders SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), an...
2023-12-12 17:00
2149
ICP DAS - BMP's Medical-Grade TPU Takes Center Stage at Top Global Medical & Plastic Exhibitions
HSINCHU, Dec. 12, 2023 /PRNewswire/ -- ICP DAS (3577-TW) New Business Unit, ICP DAS – BMP, actively ramps up medical-grade TPU (thermoplastic polyurethane) development and production as well as international marketing. The company's participation at COMPAMED and IPF Japan has been a resounding su...
2023-12-12 16:51
1846
Musim Mas Launched Women Smallholders Training Program
An expansion of the group's longstanding Smallholders Program, the first phase covered health and nutrition training; will be expanded to include financial literacy SINGAPORE, Dec. 12, 2023 /PRNewswire/ -- The Musim Mas Group announced the completion of the first phase of its Women Smallholders ...
2023-12-12 16:00
1247
Fertility Journey with Femometer Ring: Where Style Meets Precision in Ovulation Tracking
PRINCETON, N.J., Dec. 12, 2023 /PRNewswire/ -- In a groundbreaking advancement within women's health technology, the Femometer Smart Ring has emerged as a trailblazer, reshaping the landscape of basal body temperature tracking, fertility awareness for conception and overall well-being. In May 20...
2023-12-12 14:26
998
MGI Wraps Up Inaugural the Future of Omics Research Summit
DUBAI, UAE, Dec. 11, 2023 /PRNewswire/ -- MGI, a company committed to building core tools and technology to lead life science, recently concluded its inaugural The Future of Omics Research Summit, the global event focused on the field of population genomics, metagenomics research and precision me...
2023-12-12 11:09
1034
Qilu Pharmaceutical Announces Results from Phase I Clinical Study for Its Novel Bispecific Antibody QLS31905 at ESMO Immuno-Oncology Congress
JINAN, China, Dec. 12, 2023 /PRNewswire/ -- During the ESMO Immuno-Oncology Congress 2023 held inGeneva, Switzerland, from December 6th to 8th, Qilu Pharmaceutical presented the latest results of the Phase I clinical trial for QLS31905 in patients with advanced solid tumors through a poster prese...
2023-12-12 11:04
1536
Live from ASH 2023 | Ascentage Pharma Presents the First Dataset of Bcl-2 inhibitor Lisaftoclax in Patients with AML, Demonstrating Favorable Efficacy and Safety
SUZHOU, China and ROCKVILLE, Md., Dec. 11, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the results of lisaftoclax (A...
2023-12-12 09:41
2149
IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients in Oral Presentation at ASH 2023
SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 11, 2023 /PRNewswire/ -- IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, and Innovent Biologics, Inc. ("Innovent", H...
2023-12-12 03:30
1221
Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium
* ELEVATE and ELECTRA studies were designed with the objective to overcome different treatment resistance mechanisms and enhance patient outcomes with oral-oral combination options. * A preliminary analysis of data in the phase 1b part of the ELEVATE trial demonstrates antitumor activity of t...
2023-12-12 00:42
2323
Lunit Advances to Stage 2 of Australia's National Breast Cancer Screening Project
* After a successful stage 1, Lunit INSIGHT MMG moves to prospective validation inAustralia's BreastScreen NSW Machine Reading Solution Project SEOUL, South Korea, Dec. 11, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therape...
2023-12-11 22:30
1431
Inovalon Applauded by Frost & Sullivan for Improving Healthcare Delivery, Patient Outcomes, and Data Security with Its Inovalon ONE® Platform
Inovalon ONE® Platform seamlessly aggregates, standardizes, and analyzes diverse data to gain meaningful insights, support evidence-based decision-making, and offer data security and privacy. SAN ANTONIO, Dec. 11, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the healthcare analytics...
2023-12-11 22:00
1282
Yingli Pharma presents a pivotal Phase 2 study data evaluating linperlisib in relapsed or refractory peripheral T-cell lymphoma in an oral session at the American Society of Hematology 2023 Annual Meeting
Linperlisib achieved Overall Response Rate of 48% with 30% being Complete Response and manageable safety profile in the r/r PTCL phase 2 study SHANGHAI and SAN FRANCISCO, Dec. 11, 2023 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. ("Yingli Pharma"), a biopharmaceutical company focused ...
2023-12-11 21:00
1296
Zhongchao Inc. Collaborates with a Public Health Foundation to Support Sustainable and Effective Cancer Treatments
SHANGHAI, Dec. 11, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that Shanghai Zhongxin Medical Technology Co., Ltd. ("Zhongxin"),...
2023-12-11 21:00
2367
Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC for Phase III Clinical Trial
SHANGHAI, Dec. 11, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administration for the "A Randomized, Open-label, Controlled, Mu...
2023-12-11 20:00
1068
HanAll Biopharma's Partner, NurrOn Pharmaceuticals Incorporated Appoints Dr. Almira Chabi, MD, EGMP to Board of Directors
WOBURN, Mass., Dec. 11, 2023 /PRNewswire/ -- HanAll Biopharma's partner NurrOn Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related human disorders, is pleased to...
2023-12-11 20:00
1081
First Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Cancer Imaging Agent
MELBOURNE, Australia and INDIANAPOLIS, Dec. 11, 2023 /PRNewswire/ -- Telix
Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the
first patient has been dosed in aUnited States (U.S.) expanded access program
(EAP, ClinicalTrials.gov ID:NCT06090331
2023-12-11 19:40
1205
2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results
- A multi-center phase Ib/III study in China and the United States led by ProfessorBinghe Xu, MD, PhD, Academician of the Chinese Academy of Engineering - 70% of the patients enrolled in phase Ib study were previously treated with CDK4/6 inhibitors - Demonstrated a confirmed objecti...
2023-12-11 18:55
1082
Hummingbird Bioscience Strengthens Leadership Team with Appointment of Angèle Maki as Chief Business Officer
SAN FRANCISCO and SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the appointment of Angèle Maki, Ph.D., as Chief Business Offi...
2023-12-11 18:00
1350
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
[Picked up by 295 media titles]
2024-04-12 15:14
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
[Picked up by 275 media titles]
2024-04-15 08:00
Animated Life in Yunnan
[Picked up by 275 media titles]
2024-04-18 14:00
Most Read
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
2024-04-12 15:14
6410
XCMG Machinery Launches Premium G2 Crane Brand
2024-04-12 14:39
6342
DEMAND AT ASIAN FACTORIES RISES AT STRONGEST RATE IN OVER 2 YEARS, IMPROVING NEAR-TERM GROWTH OUTLOOK FOR MANUFACTURING WORLDWIDE: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
2024-04-12 20:08
4528
Sephora appoints Xia Ding as Managing Director of Sephora Greater China
2024-04-15 17:33
3796